Associations - KIT (KIT proto-oncogene, receptor tyrosine kinase)

KIT positive	Gastrointestinal Stromal Tumor	KIT positive	Gastrointestinal Stromal Tumor	imatinib Sensitive: A1 - Approval imatinib Sensitive : A1	imatinib Sensitive: A1 - Approval imatinib Sensitive : A1
KIT expression	Gastrointestinal Stromal Tumor	KIT expression	Gastrointestinal Stromal Tumor	imatinib Sensitive: A1 - Approval imatinib Sensitive : A1	imatinib Sensitive: A1 - Approval imatinib Sensitive : A1
KIT mutation	Thymic Carcinoma	KIT mutation	Thymic Carcinoma	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2
KIT exon 9 mutation	Gastrointestinal Stromal Tumor	KIT exon 9 mutation	Gastrointestinal Stromal Tumor	imatinib Resistant: A2 - Guideline imatinib Resistant : A2	imatinib Resistant: A2 - Guideline imatinib Resistant : A2
KIT mutation	Gastrointestinal Stromal Tumor	KIT mutation	Gastrointestinal Stromal Tumor	imatinib Sensitive: A2 - Guideline imatinib Sensitive : A2	imatinib Sensitive: A2 - Guideline imatinib Sensitive : A2
KIT exon 13 mutation	Melanoma	KIT exon 13 mutation	Melanoma	nilotinib Sensitive: A2 - Guideline nilotinib Sensitive : A2	nilotinib Sensitive: A2 - Guideline nilotinib Sensitive : A2
KIT mutation	Cutaneous Melanoma	KIT mutation	Cutaneous Melanoma	imatinib Sensitive: A2 - Guideline imatinib Sensitive : A2	imatinib Sensitive: A2 - Guideline imatinib Sensitive : A2
KIT mutation	Gastrointestinal Stromal Tumor	KIT mutation	Gastrointestinal Stromal Tumor	ripretinib Sensitive: B - Late Trials ripretinib Sensitive : B	ripretinib Sensitive: B - Late Trials ripretinib Sensitive : B
KIT exon 11 mutation	Gastric Cancer	KIT exon 11 mutation	Gastric Cancer	imatinib Sensitive: B - Late Trials imatinib Sensitive : B	imatinib Sensitive: B - Late Trials imatinib Sensitive : B
KIT exon 9 mutation	Gastric Cancer	KIT exon 9 mutation	Gastric Cancer	imatinib Resistant: B - Late Trials imatinib Resistant : B	imatinib Resistant: B - Late Trials imatinib Resistant : B
KIT exon 9 mutation	Gastrointestinal Stromal Tumor	KIT exon 9 mutation	Gastrointestinal Stromal Tumor	regorafenib Sensitive: B - Late Trials regorafenib Sensitive : B	regorafenib Sensitive: B - Late Trials regorafenib Sensitive : B
KIT exon 13 mutation	Melanoma	KIT exon 13 mutation	Melanoma	imatinib Sensitive: B - Late Trials imatinib Sensitive : B	imatinib Sensitive: B - Late Trials imatinib Sensitive : B
KIT mutation	Gastrointestinal Stromal Tumor	KIT mutation	Gastrointestinal Stromal Tumor	pimitespib Sensitive: B - Late Trials pimitespib Sensitive : B	pimitespib Sensitive: B - Late Trials pimitespib Sensitive : B
KIT exon 17 mutation	Gastrointestinal Stromal Tumor	KIT exon 17 mutation	Gastrointestinal Stromal Tumor	ripretinib Sensitive: B - Late Trials ripretinib Sensitive : B	ripretinib Sensitive: B - Late Trials ripretinib Sensitive : B
KIT exon 13 mutation	Gastrointestinal Stromal Tumor	KIT exon 13 mutation	Gastrointestinal Stromal Tumor	ripretinib Sensitive: B - Late Trials ripretinib Sensitive : B	ripretinib Sensitive: B - Late Trials ripretinib Sensitive : B
KIT exon 9 mutation	Gastrointestinal Stromal Tumor	KIT exon 9 mutation	Gastrointestinal Stromal Tumor	ripretinib Sensitive: B - Late Trials ripretinib Sensitive : B	ripretinib Sensitive: B - Late Trials ripretinib Sensitive : B
KIT exon 11 mutation	Gastrointestinal Stromal Tumor	KIT exon 11 mutation	Gastrointestinal Stromal Tumor	ripretinib Sensitive: B - Late Trials ripretinib Sensitive : B	ripretinib Sensitive: B - Late Trials ripretinib Sensitive : B
KIT exon 17 mutation	Gastrointestinal Stromal Tumor	KIT exon 17 mutation	Gastrointestinal Stromal Tumor	regorafenib Sensitive: B - Late Trials regorafenib Sensitive : B	regorafenib Sensitive: B - Late Trials regorafenib Sensitive : B
KIT exon 13 mutation	Gastrointestinal Stromal Tumor	KIT exon 13 mutation	Gastrointestinal Stromal Tumor	regorafenib Sensitive: B - Late Trials regorafenib Sensitive : B	regorafenib Sensitive: B - Late Trials regorafenib Sensitive : B
KIT exon 11 mutation	Gastrointestinal Stromal Tumor	KIT exon 11 mutation	Gastrointestinal Stromal Tumor	regorafenib Sensitive: B - Late Trials regorafenib Sensitive : B	regorafenib Sensitive: B - Late Trials regorafenib Sensitive : B
KIT exon 18 mutation	Gastrointestinal Stromal Tumor	KIT exon 18 mutation	Gastrointestinal Stromal Tumor	regorafenib Sensitive: B - Late Trials regorafenib Sensitive : B	regorafenib Sensitive: B - Late Trials regorafenib Sensitive : B
KIT exon 14 mutation	Gastrointestinal Stromal Tumor	KIT exon 14 mutation	Gastrointestinal Stromal Tumor	regorafenib Sensitive: B - Late Trials regorafenib Sensitive : B	regorafenib Sensitive: B - Late Trials regorafenib Sensitive : B
KIT exon 18 mutation	Gastrointestinal Stromal Tumor	KIT exon 18 mutation	Gastrointestinal Stromal Tumor	ripretinib Sensitive: B - Late Trials ripretinib Sensitive : B	ripretinib Sensitive: B - Late Trials ripretinib Sensitive : B
KIT expression	Endometrial Cancer	KIT expression	Endometrial Cancer	imatinib Sensitive: C1 - Off-label imatinib Sensitive : C1	imatinib Sensitive: C1 - Off-label imatinib Sensitive : C1
KIT mutation	Gastrointestinal Stromal Tumor	KIT mutation	Gastrointestinal Stromal Tumor	avapritinib Sensitive: C2 – Inclusion Criteria avapritinib Sensitive : C2	avapritinib Sensitive: C2 – Inclusion Criteria avapritinib Sensitive : C2
KIT exon 8 mutation	Leukemia	KIT exon 8 mutation	Leukemia	dasatinib Sensitive: C2 – Inclusion Criteria dasatinib Sensitive : C2	dasatinib Sensitive: C2 – Inclusion Criteria dasatinib Sensitive : C2
KIT exon 11 mutation	Gastrointestinal Stromal Tumor	KIT exon 11 mutation	Gastrointestinal Stromal Tumor	imatinib Sensitive: C2 – Inclusion Criteria imatinib Sensitive : C2	imatinib Sensitive: C2 – Inclusion Criteria imatinib Sensitive : C2
KIT amplification	Melanoma	KIT amplification	Melanoma	nilotinib Sensitive: C2 – Inclusion Criteria nilotinib Sensitive : C2	nilotinib Sensitive: C2 – Inclusion Criteria nilotinib Sensitive : C2
KIT exon 11 mutation	Melanoma	KIT exon 11 mutation	Melanoma	nilotinib Sensitive: C2 – Inclusion Criteria nilotinib Sensitive : C2	nilotinib Sensitive: C2 – Inclusion Criteria nilotinib Sensitive : C2
KIT exon 11 mutation	Gastrointestinal Stromal Tumor	KIT exon 11 mutation	Gastrointestinal Stromal Tumor	ponatinib Sensitive: C2 – Inclusion Criteria ponatinib Sensitive : C2	ponatinib Sensitive: C2 – Inclusion Criteria ponatinib Sensitive : C2
KIT mutation	Melanoma	KIT mutation	Melanoma	imatinib Sensitive: C2 – Inclusion Criteria imatinib Sensitive : C2	imatinib Sensitive: C2 – Inclusion Criteria imatinib Sensitive : C2
KIT mutation	Melanoma	KIT mutation	Melanoma	sunitinib Sensitive: C2 – Inclusion Criteria sunitinib Sensitive : C2	sunitinib Sensitive: C2 – Inclusion Criteria sunitinib Sensitive : C2

KIT (KIT proto-oncogene, receptor tyrosine kinase)

Associations(172)

Associations
(172)